KLF5 and liver cancer: SAHA has been shown to enhance the sensitivity to PARP inhibitors in malignant tumors such as liver cancer and acute myeloid leukemia.[44] Treatment with SAHA combined with PARP inhibitors has only been sporadically reported for OC.[45] In this study, we used a variety of OC cell lines and PDX models with high KLF5 expression to confirm the treatment efficiency and mechanism of SAHA in inhibiting the transcription of RAD51.